
Altay Therapeutics Inc. discovers novel treatments for chronic inflammatory diseases and cancers.
Altay develops novel small molecules that inhibit transcription factors that are validated drivers of disease. Our platform, enables us to identify new targets in a variety of therapeutic areas and generate inhibitors using our robust screening approach. Our mechanism of inhibition enables us to drug the "undruggable", giving us a leading advantage over our competitors.
Clinic by Q3 2022. We are focused on finding treatments for chronic inflammatory liver diseases such as NASH and liver cancer. We expect to nominate a lead drug for liver diseases by Q1 of 2021.
Our pre-clinical studies for prostate cancer and Ewings Sarcoma show great efficacy. We expect to nominate a lead for our prostate cancer program by Q2 of 2021.
Osman Nidai Ozes. PhD.
Founder and CSO
* Professor of Genetics. Mechanism of inflammatory response in cancer - Akdeniz University
* Director of Research. Lead of idiopathic lung fibrosis (IPF) program- Intermune Inc.
* Haccettepe University (B.S and M.S.) - Indiana University (PhD) - Indiana University (Postdoc)